DexCom, Inc. · NASDAQ:DXCM

DexCom — Investor Presentation (October 2022)

24 slides from DexCom's investor presentation, October 2022

  1. Slide 1: Dexcom Investor Presentation October 2022

    bexcom Dexcom Investor Presentation October 2022

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains “forward” looking statements that are based on our management's beliefs and assumptions and on information currently available to management. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-looking

  3. Slide 3: Dexcom at the core of effective care

    Dexcom at the core of effective care What we want to reinforce today: Diabetes care remains a largely unmet global need and we are providing better health outcomes Our core US market has a significant runway for further growth International markets present major opportunities for geographic expansio

  4. Slide 4: 2022 Outlook as of October 27, 2022

    2022 Outlook as of October 27, 2022 ai) FY22 Guidance ga Considerations a» Revenue of $2 88 — 2.91 billion * CGM access and awareness momentum globally (~18 - 19% Reported Growth) * Final year of significant US channel shift * FX headwinds of ~$55 million for the full-year * Gross margin impact as G

  5. Slide 5: A global crisis that remains uncontrolled

    A global crisis that remains uncontrolled Diabetes Diagnosis and Cost Adults (aged 20-79) with Diabetes Globally Source: IDF Atlas, 10th edition (2021) pexcom 537m in 2021 783m in 2045E Global Diabetes Related Health Expenditures USD USD 760 966 2019 2021 +27% Increase Past 2 Years

  6. Slide 6: 20 0

    340 320 300 280 260 240 220 200 180 160 140 120 100 80 60 40 20 0

  7. Slide 7: 20 0

    340 320 300 280 260 240 220 200 180 160 140 120 100 80 60 40 20 0

  8. Slide 8: 20 0

    340 320 300 280 260 240 220 200 180 160 140 120 100 80 60 40 20 0

  9. Slide 9: 20 0

    340 320 300 280 260 240 220 200 180 160 140 120 100 80 60 40 20 0

  10. Slide 10: 20 0

    340 320 300 280 260 240 220 200 180 160 140 120 100 80 60 40 20 0

  11. Slide 11: Core US market: momentum and opportunity remain significant

    Core US market — momentum and opportunity remain significant Insulin using population Access wins have created incu) sizable runway ~7m Our robust clinical evidence (DIAMOND, GOLD) laid the iT foundation for changes to 4m 2016 2017 2018 2019 2020 2021 ™@ Estimated US IIT CGM Users — All companies” ™

  12. Slide 12: Excellent progress on migration to pharmacy

    Excellent progress on migration to pharmacy Pharmacy access leaves us well-positioned for long-term growth We anticipate reaching our target 75% pharmacy mix in f@ 2022 Target U.S. Commercial Pharmacy Mix: 75% Current U.S. Commercial Pharmacy Mix 1. Dexcom market research. Easier to Prescribe Primar

  13. Slide 13: Workday HRIS integration

    Programs Providers Workday HRIS integration Patients Payers

  14. Slide 14: Type 2 diabetes: elements of an effective solution

    Type 2 diabetes: 3 elements of an effective solution User Health Return on Engagement Outcomes Investment <3 .y 2 pexcom %

  15. Slide 15: Type 2 in 2022: Leveraging evidence into early commercial traction

    Type 2 in 2022: Leveraging evidence into early commercial traction We are building a robust evidence base, with pilots and partnerships continuing to expand based on favorable CGM-driven results WW Intermountain’ Healthcare © onduo UT] cost savings per member per month! Glucose control drives medica

  16. Slide 16: On track to achieve goal of tripling OUS TAM

    On track to achieve goal of tripling OUS TAM New Geographies will more than __. triple our patient TAM by 2H 2023 2020:nvestor Day : ) New Geographies Core OUS Markets by 2H 2023! People using Additional people ‘mealtime insulin using mealtime insulin 1, _ Includes new countries, as well as countrie

  17. Slide 17: Gaining market share internationally

    Gaining market share internationally Improving Access * Increased or improved access for nearly 1 million individuals in 2021 in existing or core international markets Entering New Geographies Reducing Administrative Barriers Gaining Reimbursement a Driving Market ill Share Gains Leveraging E-Commer

  18. Slide 18: Dexcom ONE: Expanding access via software differentiation

    Dexcom ONE: Expanding access via software differentiation Dexcom ONE broadens our international opportunity Leverages Gé hardware platform Redesigned software experience that targets ease of use Launched as a cash pay product through Dexcom e-commerce site Compelling price point eeoeoee Represents f

  19. Slide 19: Dexcom ONE initial results

    Dexcom ONE initial results Dexcom ONE @ tons Lowe ondittacna GOSS @ ccctorimarete (ae HOO @ pexcomone Since launch, all four BELL countries have established full or partial reimbursement of Dexcom ONE for their population with Type 1 diabetes pexcom Strong Early Demand Within the first 60 days, grea

  20. Slide 20: The Dexcom CGM platform and data ecosystem

    The Dexcom CGM platform and data ecosystem Differentiating through hardware and software Pump : Connectivity 7 Clarity RT API woe r ON ---- App-in-App pexcomGé Share & Follow----------------- : oe EHR Integration pexcomG7 Where We Are Where We Are Going * Developed Markets * Developing Markets + Typ

  21. Slide 21: G7: The new standard in CGM technology

    G7: The new standard in CGM technology Fully Disposable Real-Time CGM rt) Factory Calibrated ¢@) iCGM Designed for amma Extended Wear ee | a Simple y Application a Significant & Manufacturing Cost Reduction Clarity Personalized Insights Wr Spas 7 ® 8 @ 30-Minute Warmup pexcom

  22. Slide 22: G7 trial characteristics and special controls metrics

    Primary Special Control Metrics - Adult Trial Characteristics: 2 2 Special Controls G7 US G7 US 1 1 95% LB 95% LB Point Accuracy iCGM Glucose Range <70 mg/dL Percent within +/- 15 mg/dL 85.0 90.0 92.0 Percent within +/- 40 mg/dL 98.0 99.1 99.5 iCGM Glucose Range 70-180 mg/dL Percent within +/- 15% 7

  23. Slide 23: G7: Advancing the Dexcom gold standard for sensor performance

    G7: Advancing the Dexcom gold standard for sensor performance 8.1% 8.2% Pediatric MARD! Adult MARD! 1. Dexcom submitted a comprehensive 510{k) pre-market notification to the US. Food and Drug Administration for regulatory review of the Dexcom G7 CGM System in accordance with the iCGM Special Control

  24. Slide 24: ka ls SB

    ka ls SB rosie T les Be aad, bie Me ee EY pexcom ee tak a? ye a5 s “fem

Dexcom — Investor Presentation (October 2022) on 6ix